

Supplementary material – Table 1. Patient clinical data.

ID	Ab	Age	Onset	Time to diagnosis	Cognitive decline	Seizures	Brain MRI	CSF pleocytosis (cells/mm ³)	Treatment	mRS at baseline	mRS at 1 year
Patient 1	LGI-1	77	memory impairment, neuro-behavioral disturbances, agrypnia excitata, intestinal pseudo-obstruction	6 months	at onset	yes (admitted for seizure, had also FBDS)	T2-weighted bilateral mesial temporal hyper-intensity	9	Ivlg + Iv steroid, followed by gradual steroid tapering	4	2
Patient 2	CASPR2	62	dys-autonomic features, fasciculations memory impairment	6 months	at onset	yes (admitted for telemetry)	Normal	15	Ivlg + Iv steroid, followed by gradual steroid tapering	2	0
Patient 3	GABA _B R	56	isolated memory impairment	3 months	at onset	yes (admitted for first seizure)	Normal	9	Ivlg + Iv steroid	2	0

Legend - Ab: antibody; CSF: cerebrospinal fluid; FBDS: facio-brachial dystonic seizures; Ivlg: intravenous immunoglobulin; mRS: modified Rankin scale.